You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)控股子公司獲藥品註冊批准

格隆匯5月9日丨復星醫藥(02196.HK)發佈公吿,公司控股子公司上海重慶藥友製藥有限責任公司自主研發的阿立哌唑口崩片用於治療精神分裂症的上市註冊申請於近日獲國家藥品監督管理局批准。

該新藥為集團自主研發的化學藥品,主要用於治療精神分裂症。

截至2024年3月,集團現階段針對該新藥累計研發投入約為人民幣1,035萬元(未經審計)。

截至本公吿日,除該新藥外,於中國境內(不包括港澳台地區,下同)已獲批上市的其他阿立哌唑製劑主要包括浙江大冢製藥有限公司的安律凡(阿立哌唑片)、成都康弘藥業集團股份有限公司的博思清(阿立哌唑口崩片)、上海上藥中西製藥有限公司的奧派(阿立哌唑片)等。根據IQVIACHPA最新數據,2023年,阿立哌唑製劑於中國境內的銷售額約為人民幣6.57億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account